Public Partner Gateway Open for Co-Development Clinical Pipeline Portal

The Verifiable Clinical Pipeline Zero-Animal Translation

We do not speculate on drug discovery. MetalDrug turns therapeutic logic into auditable evidence by connecting SEI scoring, ADMET-PK solvers, ExergyNet proof records, secure compute, and collaborative regulatory workspaces.

Request Partnership Access Explore the Public Ledger
4Active pipeline assets across FDC, MDC, renal, oncology, and neuro platforms.
ZKProof receipts and cryptographic lineage for compute-to-evidence workflows.
NAMDesigned around human-relevant non-animal methods and Organ-on-a-Chip evidence paths.
INDBuilt to support pre-IND planning, eCTD compilation, and partner collaboration.
// Paradigm Shift

From blind exploration to verifiable translation.

Traditional pharmaceutical pipelines are defined by high-entropy exploration. MetalDrug inverts this process by eliminating non-viable trajectories in silico before costly synthesis, validation, and regulatory compilation.

Legacy development risk

Standard discovery systems can generate large volumes of unverified compound shapes, but candidates often fail later because toxicity, bioavailability, regulatory bridging, and manufacturing logic were not resolved early enough.

The cost driver is not only compute. It is the accumulation of unsupported assumptions.

MetalDrug operating model

MetalDrug combines SEI scoring, first-principles ADMET-PK solvers, ExergyNet proof auditing, high-fidelity human-relevant assays, and regulatory document compilation.

The result is a pipeline that makes each therapeutic claim traceable to a blueprint, a simulation, a proof record, or a required evidence gap.

// Active Pipeline Portfolio

Assets engineered as verifiable therapeutic logic.

Each asset is presented as a blueprint-level evidence object: target indication, therapeutic class, regulatory rationale, preclinical verification path, ExergyNet proof hash, and current development phase.

FDC-SARCO-01 / FDC-AIM-χ3

Incretin-Wasting Co-Therapy

Phase 1b/2a Pilot Ready
Target Indication
Sarcopenia mitigation and lean mass preservation in patients undergoing GLP-1 receptor agonist therapy for obesity.
Therapeutic Class
Multi-modal Functional Drug Complex, oral and transdermal.
Regulatory Path
505(b)(2) safety bridge relying on constituent small molecule safety histories.

Preclinical Verification

  • Skeletal Muscle-on-a-Chip: PM module retains 93% twitch force under induced catabolic stress and drives 2.8-fold follistatin secretion.
  • Liver-on-a-Chip: AM module reverses hepatic steatosis by 31% via AMPK activation with zero ALT/AST leakage at 10x therapeutic concentration.

Proof Record

0x7f3e1a8b9c6d5e4f... · LO TXT Explorer Verified
MDC-DOX-001 / FDC-DOX-α1

Targeted Oncology

Pre-IND Staged
Target Indication
Targeted cytotoxicity in solid tumors and sarcomatoid cancers.
Therapeutic Class
Metal-Coordinated Drug Complex.
Regulatory Rationale
Tumor-selective doxorubicin payload delivery through pH/ROS-cleavable hydrazone linker coordinated to octahedral Ruthenium.

Preclinical Verification

  • High-affinity binding: Kd 9.4 nM under on-chain transaction JOB-BDDD83EA.
  • Cardiac-Tissue-on-a-Chip: hERG IC50 >150 uM and stable APD90 profile.

Proof Record

0xbf10a3a9357e7c1c... · LO TXT Explorer Verified
QRX-3

The Mitochondrial Rescue Asset

Phase 2/3 Active Evaluation
Target Indication
Chronic Kidney Disease with severe mitochondrial decay.
Therapeutic Class
Fixed-Dose Combination: Acetylcysteine, Ubiquinone, Pentoxifylline.
Registry Reference
NCT06866236.

Regulatory Precedent

  • Original IND issue: missing animal toxicology and incomplete bridging logic.
  • SEI intervention: nonclinical pharmacology, PK models, and batch stability records compiled in silico within a 20-day window.
  • Outcome record: internal pipeline states FDA CDER accepted the in-silico bridge and hold was lifted in under 30 days.

Proof Record

0x4674674fcca76ff7... · LO TXT Explorer Verified
FDC-NEURO-M4

Cognitive Support Platform

Tier 2 Verified
Target Indication
Neuroprotection and glymphatic detoxification in early-stage Alzheimer's and Parkinson's disease.
Therapeutic Class
CNS-Selective Functional Drug Complex.
Regulatory Rationale
Selective M4 muscarinic receptor activation with cysteine-zinc coordination to buffer localized oxidative stress.

Preclinical Verification

  • BBB penetration checked through Henderson-Hasselbalch ionization gating at physiological pH 7.4.
  • Glymphatic clearance simulation models astrocyte AQP4 polarization states and sleep-dependent neurotoxin drainage.

Proof Record

0x81b944c8e7bada03... · LO TXT Explorer Verified
// Partnership Invitation

Co-develop on the Moleculogic Operating System.

Research groups, startups, and pharmaceutical enterprises can bring biological targets, run verified simulations, and co-compile IND-ready evidence inside secure regulatory workspaces.

01

Bring Your Own Target

Generate target protein coordinates using AlphaFold Server or an equivalent structural source, then upload the .pdb file into the secure ingestion workflow.

02

Run Verifiable Simulations

Use the ExergyNet prover swarm for ADMET-PK, DDI-interaction, temporal decoupling, screening, and proof-backed compute outputs.

03

Co-Compile in Deal Rooms

Invite researchers, CRO partners, and consultants into a regulatory workspace with Logic Guard checks, evidence attachments, and eCTD-oriented compilation.

// Open for Business

Request secure Tier 2/3 access.

Contact Business Development and Licensing to initiate a custom co-development workspace, verified compute pathway, or regulatory evidence package.

Contact Us Licensing
Audit ID: AID-2026-0526-0158 · Status: Validated · Anchor: SEI-CLINICAL-PIPELINE-v1.0